Truncation of Pik3r1 causes severe insulin resistance uncoupled from obesity and dyslipidemia by increased energy expenditure by Kwok, Albert et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Truncation of Pik3r1 causes severe insulin resistance uncoupled
from obesity and dyslipidemia by increased energy expenditure
Citation for published version:
Kwok, A, Zvetkova, I, Virtue, S, Luijten, I, Huang-doran, I, Tomlinson, P, Bulger, DA, West, J, Murfitt, S,
Griffin, J, Alam, R, Hart, D, Knox, R, Voshol, P, Vidal-puig, A, Jensen, J, O’rahilly, S & Semple, RK 2020,
'Truncation of Pik3r1 causes severe insulin resistance uncoupled from obesity and dyslipidemia by
increased energy expenditure', Molecular Metabolism, pp. 101020.
https://doi.org/10.1016/j.molmet.2020.101020
Digital Object Identifier (DOI):
10.1016/j.molmet.2020.101020
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Version created as part of publication process; publisher's layout; not normally made publicly available
Published In:
Molecular Metabolism
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 21. Jun. 2020
Journal Pre-proof
Truncation of Pik3r1 causes severe insulin resistance uncoupled from obesity and
dyslipidemia by increased energy expenditure
Albert Kwok, Ilona Zvetkova, Sam Virtue, Ineke Luijten, Isabel Huang-Doran, Patsy
Tomlinson, David A. Bulger, James West, Steven Murfitt, Julian Griffin, Rafeah Alam,
Daniel Hart, Rachel Knox, Peter Voshol, Antonio Vidal-Puig, Jørgen Jensen, Stephen
O’Rahilly, Robert K. Semple
PII: S2212-8778(20)30094-6
DOI: https://doi.org/10.1016/j.molmet.2020.101020
Reference: MOLMET 101020
To appear in: Molecular Metabolism
Received Date: 6 February 2020
Revised Date: 5 May 2020
Accepted Date: 12 May 2020
Please cite this article as: Kwok A, Zvetkova I, Virtue S, Luijten I, Huang-Doran I, Tomlinson P,
Bulger DA, West J, Murfitt S, Griffin J, Alam R, Hart D, Knox R, Voshol P, Vidal-Puig A, Jensen J,
O’Rahilly S, Semple RK, Truncation of Pik3r1 causes severe insulin resistance uncoupled from obesity
and dyslipidemia by increased energy expenditure, Molecular Metabolism, https://doi.org/10.1016/
j.molmet.2020.101020.
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2020 Published by Elsevier GmbH.
Truncation of Pik3r1 causes severe insulin resistance uncoupled from obesity 1 
and dyslipidemia by increased energy expenditure 2 
 3 
SHORT TITLE: Insulin resistance without lipotoxicity due to Pik3r1 mutation 4 
 5 
Albert Kwok1,2, Ilona Zvetkova1,2, Sam Virtue1,2, Ineke Luijten3, Isabel Huang-6 
Doran1,2, Patsy Tomlinson1,2, David A. Bulger1,2, James West4, Steven Murfitt4, Julian 7 
Griffin4,8, Rafeah Alam5, Daniel Hart1,2, Rachel Knox1,2, Peter Voshol6, Antonio Vidal-8 
Puig1,2, Jørgen Jensen7, Stephen O’Rahilly1,2, Robert K Semple3,1,2 9 
 10 
1The University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC 11 
Institute of Metabolic Science, Cambridge, UK 12 
2MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Science, 13 
Cambridge, UK 14 
3Centre for Cardiovascular Science, University of Edinburgh, 47 Little France Crescent, 15 
Edinburgh, UK 16 
4Department of Biochemistry and Cambridge Systems Biology Centre, University of 17 
Cambridge, Cambridge, UK 18 
5Laboratory of Lymphocyte Signalling and Development, The Babraham Institute, 19 
Cambridge, UK 20 
6Louis Bolk Institute, Kosterijland 3-5, NL-3981AJ, Bunnik, The Netherlands 21 
7Department of Physical Performance, Norwegian School of Sport Sciences, P.O. Box 4014, 22 
Ulleval Stadion, 0806 Oslo, Norway 23 
8Biomolecular Medicine, Division of Systems Medicine, Department of Metabolism, Digestion 24 
and Reproduction, Medicine, Imperial College London, The Sir Alexander Fleming Building, 25 
London, UK 26 
 27 
Correspondence to: 28 
Prof. Robert K. Semple, Centre for Cardiovascular Science, University of Edinburgh, 29 
Queen’s Medical Research Institute, Little France Crescent, Edinburgh EH16 4TJ, 30 
UK. Tel: +44 131 242 6051/ Email: rsemple@ed.ac.uk 31 
 32 
  33 
 2
SUMMARY1 1 
Objective: Insulin signaling via phosphoinositide 3-kinase (PI3K) requires PIK3R1-2 
encoded regulatory subunits.  C-terminal PIK3R1 mutations cause SHORT 3 
syndrome, including lipodystrophy and insulin resistance (IR), surprisingly without 4 
fatty liver or metabolic dyslipidemia.  We sought to investigate this discordance.   5 
Methods: The human pathogenic Pik3r1 Y657* mutation was knocked into mice by 6 
homologous recombination. Growth, body composition, bioenergetic and metabolic 7 
profiles were investigated on chow and high fat diet.  Adipose and liver histology was 8 
examined, and liver responses to fasting and refeeding assessed transcriptomically. 9 
Results: Like humans with SHORT syndrome, Pik3r1Y657*/WT mice were small with 10 
severe IR, and adipose expansion on high fat diet was markedly reduced.  Also like 11 
humans, plasma lipid concentrations were low, and insulin-stimulated hepatic 12 
lipogenesis was not increased despite hyperinsulinemia. At odds with lipodystrophy, 13 
however, no adipocyte hypertrophy nor adipose inflammation was found.  Liver 14 
lipogenic gene expression was not significantly altered, and unbiased 15 
transcriptomics showed only minor changes, including evidence of reduced 16 
endoplasmic reticulum stress in the fed state and diminished Rictor-dependent 17 
transcription on fasting. Increased energy expenditure, which was not explained by 18 
hyperglycemia nor intestinal malabsorption, provided an alternative explanation for 19 
uncoupling of IR from dyslipidaemia. 20 
Conclusions: Pik3r1 dysfunction in mice phenocopies the IR and reduced adiposity 21 
without lipotoxicity of human SHORT syndrome. Decreased adiposity may not reflect 22 
bona fide lipodystrophy, but rather increased energy expenditure, and we suggest 23 
that study of brown adipose tissue in both humans and mice is warranted.   24 
 25 
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1
 Abbreviations: IR = insulin resistance; PI3K = phosphoinositide 3-kinase; SHORT syndrome = Short 
stature, Hyperextensibility of joints, Ocular depression, Rieger anomaly of the iris, and Teething delay; 
RER = Respiratory Exchange Ratio; HFD = High Fat Diet 
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1. Introduction 1 
Adipose tissue is essential for metabolic health in the face of sustained positive 2 
energy.  When adipose expansion is constrained, as in lipodystrophy, its capacity to 3 
sequester excess energy and serve as a physiological “energy buffer” is 4 
overwhelmed [1].  Injury and inflammation of any residual adipose tissue ensues, 5 
causing systemic inflammation and rerouting substrates to liver, pancreas and 6 
muscle.  Insulin resistance (IR), diabetes, aggressive fatty liver disease, and 7 
severely elevated plasma lipoprotein concentrations are thus common 8 
consequences of lipodystrophy [2]. 9 
SHORT syndrome (short stature, hyperextensibility of joints, ocular 10 
depression, Rieger anomaly of the iris, and teething delay) is a human monogenic 11 
syndrome including lipodystrophy [3–5].  This form of lipodystrophy is highly unusual, 12 
as although associated with insulin resistant diabetes [3–5], it is uncoupled from fatty 13 
liver and dyslipidemia [6].  SHORT syndrome also does not feature the suppressed 14 
plasma adiponectin concentration seen in common IR and other lipodystrophies [7], 15 
showing that “insulin resistance syndrome” components are dissociable. 16 
SHORT syndrome is caused by mutations in PIK3R1, encoding components of 17 
the insulin signaling enzyme phosphoinositide 3-kinase (PI3K) [3–5].  The PI3K 18 
subtype required for insulin action comprises a p110α catalytic subunit bound to a 19 
regulatory subunit, three of which - p85α, p55α and p50α – are encoded by PIK3R1.  20 
PIK3R1 products stabilise catalytic subunits, mediating their recruitment to receptor 21 
tyrosine kinases or their substrates, including the insulin receptor and IRS1 [8,9].   22 
Before discovery of PIK3R1 mutations in SHORT syndrome, Pik3r1 had been 23 
intensively studied in mice.  Selective p85α deficiency [10][11] or deletion of p50α 24 
and p55α [12] surprisingly enhances insulin sensitivity, which has been accounted 25 
for by compensation by other regulatory subunits, and/or altered stoichiometry of 26 
catalytic and regulatory subunits.  A critical insight from study of SHORT syndrome 27 
 4
was that the insulin signaling role of PIK3R1 could be severely attenuated by 1 
neomorphic mutations disrupting the C terminal SH2 domain [3–5]. Such dominant 2 
negative PIK3R1 alleles, which severely reduce insulin-induced activation of PI3K 3 
without abolishing expression of PI3K, offer the opportunity to interrogate in vivo 4 
pathophysiological roles of PI3K activity in IR more precisely than possible to date.  5 
In human lipodystrophy, de novo lipogenesis contributes significantly to liver 6 
triglyceride and plasma lipid content [13].  In contrast, mutations in the INSR gene, 7 
encoding the insulin receptor, produce extreme IR with normal plasma lipid profile, 8 
normal liver lipid content, and no increase in hepatic de novo lipogenesis [13].  9 
Furthermore murine models with knockout of any one of several components of the 10 
insulin signaling pathway (Insr [14], Irs1 and Irs2 [15], p85α and β [16], Pik3ca [17], 11 
or Rictor [18]) demonstrate that liver insulin signaling drives hepatic de novo 12 
lipogenesis.  We thus hypothesised that in SHORT syndrome the liver is protected 13 
from increased insulin-mediated lipogenesis, which is relatively unaffected by 14 
common IR [19], and that this explains the absence of dyslipidemia and fatty liver 15 
despite severe IR and lipodystrophy. 16 
We report a novel murine SHORT syndrome model caused by a human 17 
pathogenic allele, Y657*, that reproduces uncoupling of metabolic dyslipidemia from 18 
severe IR. Surprisingly hepatic lipogenic transcriptional programmes were minimally 19 
perturbed, although metabolic inflexibility with a dyscoordinated fasting response 20 
was seen. Adipose tissue accumulation was reduced on high fat feeding.  We 21 
suggest that this is related to increased energy expenditure, likely via brown adipose 22 
tissue, rather than lipodystrophy, with hypolipidemia attributable to increased fuel 23 
oxidation.  This potential explanation for the unusual IR subphenotype of SHORT 24 
syndrome warrants testing in humans with SHORT syndrome or other defects in 25 
proximal insulin signaling.  26 
 27 
2. Materials and Methods 28 
 5
2.1 Mice generation and maintenance  1 
The Pik3r1 Y657* mutation and a neomycin resistance cassette flanked by 2 
LoxP sites were introduced into C57Bl/6 embryonic stem cells by homologous 3 
recombination before injection into Bl/6J blastocysts (Supplemental Figure S1). 4 
Animals were kept on a C57Bl/6J background, backcrossed at least three times, and 5 
housed on a 12-hour-light/12-hour-dark cycle at 23°C, with ad libitum food and water 6 
access. Feeding was with chow (Catalogue no. 105, Safe diets) or 45% fat diet (45% 7 
fat, 35% Carbohydrate and 25% protein) (Catalogue no. D12451, Research diet, 8 
Inc). Experiments were carried out under the UK Home Office Animals (Scientific 9 
Procedures) Act 1986, following University of Cambridge ethical review. 10 
2.2 Assessment of growth, body composition, and energy homeostasis 11 
Body composition was determined by time-domain NMR with Bruker’s 12 
minispec analyser. For food intake and energy expenditure measurement, male mice 13 
were acclimatized for 1 week to single housing then given chow or 45% fat diet for 14 
10 days.  Food intake was measured daily and energy expenditure measured by 15 
indirect calorimetry [20]. Locomotor activity was quantified as beam breaks over 48 16 
hours.  Fecal energy content was measured by combusting dried feces from 48hr 17 
calorimeter runs in an IKA Calorimeters Oxygen Bomb calorimeter (IKA C1). 18 
2.3 In vivo metabolic studies 19 
For fasting/refeeding studies, mice were fed chow ad libitum until 16 weeks 20 
before 16 hours fasting then 6 hours refeeding with chow. Tissues were harvested 21 
and snap frozen prior to overnight fasting, or after fasting or after refeeding. For 22 
study of insulin action 16 hour-fasted mice (16 weeks old) were injected with 2U/kg 23 
insulin intraperitoneally and tissues collected after 10 minutes and snap frozen. 24 
Glucose tolerance testing was undertaken on overnight (16 hour) fasted mice using 25 
2g/kg 20% glucose via oral gavage.  For insulin tolerance testing 6 hour-fasted mice 26 
were given 0.5U/kg intraperitoneal insulin. For lipid tolerance testing 16 hour-fasted 27 
mice were administered 10mL/kg olive oil by gavage.  28 
 6
Hyperinsulinemic euglycemic clamp studies and subsequent sample 1 
processing and analysis were conducted as described previously [21] on 16 week 2 
old mice after overnight fasting.  Clamps used a priming dose of human insulin (0.7 3 
mU), followed by constant insulin and [3-3H]-D-glucose infusion at 7 mU/h and 0.72 4 
μCi/h, respectively. 5 
2.4 Study of tissue insulin responsiveness ex vivo 6 
Measurement of insulin action on isolated Soleus and Extensor Digitorum 7 
Longus was undertaken in 16 week old male mice as described[22].  For primary 8 
preadipocyte differentiation studies fat pads from 8 week-old male mice were 9 
isolated and cultured as described [20], but without 5-Triiodo-l-thyronine. 10 
2.5 Biochemical assays 11 
Blood was collected by cardiac puncture and plasma snap frozen before 12 
assays detailed in supplemental Table 3. Glycogen content of snap-frozen liver used 13 
glycogen hydrolysis in 1 M HCl (2.5 h at 100°C), NaOH neutralization and 14 
fluorometric glucose analysis [23].  Hepatic triglyceride determination used a 15 
Triglyceride Colorimetric Assay kit (Cayman). Hepatic cholesterol was extracted from 16 
10mg liver using 400uL chloroform:isopropanol:NP-40 mixture (7:11:0.1) before 17 
centrifugation, 30min vacuum drying (50°C) and dissolving in PBS. The samples 18 
were assayed by Siemens Healthcare Diagnostics kit.  19 
2.6 Metabolomic Studies 20 
Liver metabolites were extracted from tissue snap-frozen after dissection using 21 
a reported methanol/chloroform method [24]. Aqueous metabolites were further 22 
extracted as described in [24] and analysed using a Vanquish ultra-high 23 
performance liquid chromatography (UHPLC) system and TSQ Quantiva triple 24 
quadrupole mass spectrometer (Thermo Scientific) with compounds directly infused. 25 
Parameter optimisation used 1µM standard solutions in chromatographic buffer. 26 
Optimal mass spectrometry parameters and mass transitions were generated by 27 
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automatic MassLynx™ (Version 1.4, Waters) protocols or, if standards were 1 
unavailable, deduced from known analogue parameters. 2 
2.7 Assessment of de novo lipogenesis 3 
16 week chow-fed mice were fasted overnight, injected intraperitoneally with 4 
deuterated saline (24 uL/g), and given high carbohydrate diet (Harlan Teklad Diets, 5 
Cat no. TD88232) and 4% deuterated water (Goss Scientific Instruments Ltd, Cat 6 
no. DLM-2259) from 1- 24 hours later. After culling livers were snap-frozen and 7 
50mg homogenised in 600uL methanol-chloroform (2:1) before extraction and 8 
analysis as described [25]. 9 
2.8 Histology  10 
Size of at least 1000 adipocytes per genotype from 16 week old chow-fed mice was 11 
measured in FFPE tissue as described [26]. Adipose Treg cells were isolated and 12 
counted by FACS, also as reported [27]. 13 
2.9 Gene expression analysis 14 
For protein studies fresh tissues were snap-frozen in liquid nitrogen, and 15 
homogenised using MD ceramic beads in RIPA buffer with proteinase/phosphatase 16 
inhibitors (liver, muscle)(Roche) or mortar and pestle in liquid nitrogen before 17 
dissolving in buffer (adipose). Protein concentrations were determined by BCA assay 18 
(BioRad). Western blotting employed the Novex gel system (Thermo Fisher 19 
Scientific). Antibodies are shown in Supplemental Table S4.  Quantification 20 
employed the BioRad image system.  21 
Total RNA was extracted and reverse transcribed for qPCR as previously 22 
described [28]. Target expression was normalised to the geometric mean of 4 23 
housekeeping genes (Ywhaz, Ppia, B2m and Eef1a1) (Supplemental Table S4 for 24 
primer/probe sequences).  RNA sequencing protocols and analysis have previously 25 
been reported [29].    26 
2.10 Statistical Analysis 27 
 8
D'Agostino & Pearson or Shapiro-Wilk tests were performed to test for 1 
Gaussian distribution of data. For Gaussian data unpaired two-tailed Student’s t 2 
tests for two group comparison and ANOVA with post hoc for multiple group 3 
comparison were performed using GraphPad Prism (GraphPad Software).  For non 4 
Gaussian data Mann-Whitney testing was used for two group comparison and 5 
Kruskal-Wallis and Dunn’s multiple comparison testing were used for multiple group 6 
analysis using GraphPad Prism (GraphPad Software). Tissue weights, food 7 
consumption and energy expenditure were analyzed by ANCOVA using XLSTAT 8 
(Addinsoft).    9 
2.11 Data and Resource Availability 10 
All transcriptomic data were deposited in GEO under accession number XXXX 11 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=XXXX).  Other datasets, and 12 
the Pik3r1Y657*/WT mice generated during the current study are available from the 13 
corresponding author upon reasonable request. 14 
 15 
3. Results 16 
3.1 Growth and development of Pik3r1 Y657* knock-in mice 17 
Mice harbouring the Pik3r1 Y657* mutation were generated by homologous 18 
recombination-based gene targeting (Figure S1A).  Immunoblotting confirmed 19 
expression of truncated p85α at greater amounts than full length protein in most 20 
tissues, likely due to loss of a ubiquitylation motif located beyond the nonsense 21 
mutation in the C-terminal [30].  No compensatory change in PI3K p85β subunit was 22 
seen.  p110α subunit expression was reduced in subcutaneous white adipose tissue, 23 
and p110β expression was reduced in liver, subcutaneous and epididymal white 24 
adipose tissue (Figure S1B).   25 
No Pik3r1Y657*/Y657* embryos were identified beyond E11.5.  At E11.5 they were 26 
smaller, with poorly developed limb buds and reduced eye pigmentation. 27 
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Heterozygous embryos were smaller from E15.5 (Figure S2A-E).   Pik3r1WT/Y657* 1 
mice were born at expected frequency but showed impaired linear growth and body 2 
weight on chow (Figure 1A-C). At 16 weeks there was a small decrease in whole 3 
body adiposity (Figure 1D), however no difference was found in epididymal or 4 
inguinal white adipose nor interscapular brown adipose depot weights when lean 5 
mass was taken into account (Figure 1E-G).  Plasma leptin concentrations were 6 
similar in male Pik3r1WT/Y657* and wild-type mice (3.3±1.2 vs 2.6±0.3 µg/L on fasting 7 
(n=9,10; NS); 10.3±2.2 vs 15.9±3.9 µg/L on ad libitum feeding (n=13,13; NS)). Liver 8 
weights were indistinguishable (Figure 1H), but hearts were heavier in Pik3r1WT/Y657* 9 
mice (Figure 1I). No difference in food consumption nor energy expenditure was 10 
seen at 16 weeks on chow (Figure 1J,K), however the respiratory exchange ratio 11 
(RER) was higher during the light phase in Pik3r1WT/Y657* mice, blunting circadian 12 
fluctuation (Figure 1L). Similar differences were seen between heterozygous and 13 
wild-type females for all variables assessed in both sexes.  14 
3.2 Response of Pik3r1WT/Y657* mice to a high fat diet 15 
To assess whether placing a greater load on adipose tissue in Pik3r1WT/Y657* 16 
mice would unmask lipodystrophy, mice were fed a 45% fat diet (HFD) from 8 weeks 17 
old. Pik3r1WT/Y657* mice showed reduced gain of weight and body fat over the 8 18 
weeks studied (Figure 2A,B).  Epididymal white adipose tissue was most severely 19 
affected (Figure 2C), with no significant difference in inguinal nor brown adipose 20 
tissue (Figure 2D,E).  Lean mass did not increase at a greater rate in Pik3r1WT/Y657* 21 
mice (Figure S3A,B), and liver weights also did not differ, while heart weights were 22 
elevated in heterozygotes, as on chow (Figure 2F,G).  Consistent with reduced 23 
adiposity, Pik3r1WT/Y657* mice had lower serum leptin concentration when fed 24 
(37.7±7.3 vs 11.3±2.0 µg/L (n=15,11; p=3x10-3)), but not fasted (15.9±3.9 vs 25 
10.3±2.2 µg/L (n=13,13; not significant)), while adiponectin concentrations were 26 
unchanged (Table 1). 27 
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Given reduced adipose expansion, we next sought histological evidence of 1 
“adipose failure”, namely adipocyte hypertrophy and inflammation, which would be 2 
expected in lipodystrophy when adipose expansion is pathological constrained, 3 
causing adipose injury on positive energy balance.  The histological appearance and 4 
adipocyte size distribution in epididymal adipose tissue was indistinguishable 5 
between genotypes (Figure 2H,I), however, with no evidence of inflammation, nor 6 
fibrosis.  Consistent with the lack of histological evidence of adipose overload, ex 7 
vivo differentiation of preadipocytes from inguinal or epididymal depots was 8 
unaltered (Figure 2J).  Finally, given the role of Pik3r1 in lymphocyte function, and 9 
the important role of adipose-resident T regulatory (Treg) cells in energy homeostasis, 10 
the adipose content of Treg cells was assessed by FACS. No major difference was 11 
observed between genotypes (Figure 2K).  12 
Given these findings, which are at odds with a true lipodystrophy, we next 13 
assessed whether reduced adipose accretion instead reflected altered energy 14 
homeostasis. Pik3r1WT/Y657* mice exhibited increased food intake (Figure 2L) and 15 
energy expenditure (Figure 2M) when the size of the animals was taken into 16 
account, but locomotor activity was unchanged across 24 hours (Figure 2N).  17 
Markedly reduced accumulation of adipose tissue despite increased food intake, and 18 
without sustained hyperglycemia, demonstrates severely reduced food efficiency.  19 
This indicates that increased food intake is a compensatory response to chronically 20 
increased energy expenditure rather than a primary phenomenon.  As on chow, the 21 
circadian RER profile was blunted, with higher values in the dark phase and no 22 
discernible difference between light and dark phases for Pik3r1WT/Y657* mice (Figure 23 
2O), suggesting greater carbohydrate oxidation in the dark phase.   24 
3.3 Pik3r1WT/Y657* mice are severely insulin resistant 25 
At 12 weeks old, neither male nor female Pik3r1WT/Y657* mice on chow were 26 
hyperglycemic compared to controls, but plasma insulin concentrations were raised, 27 
more severely on feeding (Tables 1 and S1).  On high fat feeding male Pik3r1WT/Y657* 28 
 11
mice remained hyperinsulinemic, but the difference between mutant and control 1 
mice was abolished by the greater increase in insulin concentrations in wild-type 2 
mice.  Blood glucose concentration was paradoxically lower in fed Pik3r1WT/Y657* mice 3 
on high fat diet.  Plasma adiponectin concentrations in fasted chow-fed Pik3r1WT/Y657* 4 
mice were lower than in wild-type controls, however no significant difference was 5 
seen in other conditions despite the severe IR of heterozygous mice (Table 1). In 6 
Pik3r1WT/Y657* mice on HFD, adiponectin normalised to body fat was higher than in 7 
controls, reminiscent of the preserved adiponectin seen in severely insulin resistant 8 
patients with SHORT syndrome [7]. Normalised plasma leptin concentrations, in 9 
contrast, were lower (Figure S3C,D). 10 
Hyperinsulinemic euglycemic clamps were undertaken on chow- and HFD-fed 11 
male mice.  Chow-fed Pik3r1WT/Y657* mice required a steady state glucose infusion 12 
rate of only one eighth that required by wild-type mice, confirming severe IR (Figure 13 
3A).  On HFD Pik3r1WT/Y657* mice remained extremely insulin resistant, however the 14 
difference between genotypes was much smaller than on chow due to increased IR 15 
in wild-type animals (Figure 3A).  Further studies were thus undertaken on chow.  16 
Glucose and insulin excursions on oral glucose tolerance testing showed a trend 17 
towards an increase in male Pik3r1WT/Y657* mice (Figure 3B,C), but were increased in 18 
female mice (Figure S4A,B), while the hypoglycemic response to insulin was 19 
attenuated in both sexes (Figures 3D and S4C). Clamp studies in males using 20 
isotopic tracers showed glucose disposal to be 19% lower in Pik3r1WT/Y657* mice 21 
(Figure 3E) while suppression of hepatic glucose production by hyperinsulinemia 22 
was 49% lower compared to wild type littermates (Figure 3F). Despite this, liver 23 
glycogen content was similar between genotypes (Figure 3G).  Insulin infusion 24 
lowered plasma free fatty acid concentration in wild-type mice, but little suppression 25 
was seen in heterozygous mice, consistent with impaired suppression of adipose 26 
lipolysis (Figure 3H). 27 
 12
Intraperitoneal insulin in male mice strongly induced Akt phosphorylation in 1 
liver, skeletal muscle and epididymal and inguinal adipose tissue of wild-type 2 
controls, as expected, and this was reduced in Pik3r1WT/Y657* mice (Figures 3I-L and 3 
S5A-D).  As muscle insulin sensitivity was previously reported not to be reduced in 4 
Pik3r1WT/R649W mice [31], insulin responsiveness of soleus and extensor digitorum 5 
longus (EDL) muscles was assessed ex vivo.  Soleus and EDL muscle from 6 
Pik3r1WT/Y657* mice both showed a 1.3-fold reduction in insulin-stimulated 7 
deoxyglucose uptake compared to wild-type muscle (Figure 3M). Insulin-induced 8 
Akt phosphorylation was also markedly reduced in both types of muscle ex vivo to a 9 
much more significant degree than in vivo (Figures 3N,O and S5E).  This finding of 10 
muscle insulin resistance using several different techniques, although at odds with 11 
clamp studies reported previously, is consistent with the robust expression of Pik3r1 12 
gene products in skeletal muscle.    13 
 14 
3.4 Pik3r1WT/Y657* mice are hypolipidemic  15 
Having shown that, as in SHORT syndrome, heterozygous Pik3r1WT/Y657* mice 16 
show severe IR and reduced adiposity, we assessed whether, like humans, they do 17 
not exhibit fatty liver nor metabolic dyslipidemia. In fed and fasting states, on either 18 
chow or high fat diets, Pik3r1WT/Y657* mice showed hypolipidemia, with lower plasma 19 
total cholesterol and HDL cholesterol (Table 1).  This was most striking in fed mice 20 
on high fat diet, mirroring the lower glucose seen in Pik3r1WT/Y657* mice in this state.  21 
Plasma triglyceride concentration was also lower in heterozygous animals in all 22 
states except when fasting state after HFD, and plasma free fatty acid concentration 23 
was lower in all states except in fed animals maintained on chow.  Similar 24 
hypolipidemia was seen in chow-fed female mice on fasting (Table S1). No 25 
difference was seen in VLDL concentrations in chow- or high fat-fed mice (Table 1).   26 
Despite severe IR in Pik3r1WT/Y657* mice, no difference was seen in liver 27 
triglyceride content compared to controls either on chow or HFD, assessed by Oil-28 
 13
Red-O staining and biochemical quantification (Figure 4A,B).  Liver cholesterol 1 
content was also the same in chow-fed animals of both genotypes (Figure 4C).  Oral 2 
lipid tolerance testing revealed similar triglyceride excursion after lipid loading in both 3 
genotypes (Figure 4D), and bomb calorimetry of feces on chow showed the same 4 
energy content (Figure 4E), excluding abnormal intestinal lipid handling as the 5 
explanation for hypolipidemia and reduced adiposity. 6 
Insulin stimulates hepatic de novo lipogenesis and cholesterogenesis via  7 
Srebp1 and Srebp2 respectively. In prevalent IR, hepatic de novo lipogenesis is 8 
enhanced, and the mismatch between this and the reduced hypoglycemic action of 9 
insulin is evidence for “partial IR” in metabolic dyslipidemia [19].  Liver PI3K 10 
mediates the action of insulin on lipogenesis, with hypolipidemia despite IR seen in 11 
numerous models in which hepatic insulin/Irs/PI3K/Akt2/mTORC2 signaling is 12 
impaired [14–16,18,32].  Based on these findings, we hypothesised that the 13 
hypolipidemia seen in Pik3r1Y657*/WT mice would be accounted for by reduced hepatic 14 
de novo lipogenesis, as in SHORT syndrome due to PIK3R1 Y657*[7].  In keeping 15 
with this, no increased de novo synthesis of palmitate could be measured in 16 
heterozygotes despite fasting hyperinsulinemia and refeeding with a high 17 
carbohydrate diet (Figure 4F).  Liver mRNA expression of Srebp1c, Srebp2 and key 18 
target genes (Acc1, Fasn, Scd1 and Mvk, Nsdhl, respectively) was also determined 19 
in chow-fed animals in fed, fasting and refed states, and no difference was seen in 20 
expression of any of these genes under any nutritional conditions (Figure 4G-M).   21 
Other transcriptional regulators relevant to hypolipidemia include carbohydrate 22 
response element binding protein (Chrebp) and Xbp1, with the latter binding p85α 23 
and facilitating its nuclear translocation [31,33,34]  A sentinel Chrebp-responsive 24 
gene (Pklr) showed mild but significant reduction of mRNA in the fasting state, but 25 
mRNA of two Xbp1 target genes (Acacb and Dgat2) showed no reduction during a 26 
fasting refeeding cycle (Figure S6A-C).  It has also been proposed that modulation 27 
of the ratio between Glucose-6-phosphatase (G6pc) and Glucokinase (Gck) toggles 28 
 14
hepatocyte glucose flux between lipogenesis and glucose production, and that this 1 
operates before transcriptional changes in lipogenic transcription factors [35].  2 
However, although an increase in G6pc:Gck liver transcript levels was seen on 3 
fasting of wild-type mice, the ratio was suppressed in Pik3r1WT/Y657* mice, as reported 4 
in mice on Western-type diet [35] (Figure S6D-F).  We conclude that the consistent 5 
hypolipidemia seen in Pik3r1WT/Y657* mice does not correlate with attenuated insulin-6 
induced lipogenesis in the liver, suggesting that the reduced blood lipid 7 
concentrations are not explained by attenuation of insulin’s lipogenic actions. 8 
Given lack of transcriptional perturbation of known lipogenic factors, global 9 
liver transcriptomic analysis was undertaken in fed and 16 hour fasted states.   10 
Genotypes were compared in each state, and fasting gene expression was 11 
compared to fed gene expression for both genotypes. Gene-based analysis 12 
confirmed prior findings, but provided no obvious alternative explanation for 13 
hypolipidemia.  Pathway analysis of predicted upstream regulators showed modest 14 
but significant differences in the fed state, with a transcriptional signature of reduced 15 
ER stress (upstream regulators Xbp1, its processing enzyme Ern1 (Ire1), and Atf6), 16 
and altered signatures of several cytokines including IL6 (reduced), IL21, interferons 17 
gamma and alpha 2 (increased)(Figure 5, Table S2). More significant differences 18 
were seen after 16-hour fasting, when a transcriptional profile consistent with 19 
reduced activity of Rictor, the defining component of mTORC2, was seen with high 20 
significance, while patterns associated with Myc and Mycn were upregulated.  The 21 
large preponderance of changes observed between fed and fasting states in wild 22 
type mice, including strong upregulation of PPARα-responsive genes, was 23 
conserved in heterozygous animals, however (Figure 5, Table S2).  24 
In view of transcriptomic evidence of reduced Rictor activity, plasma and 25 
hepatic amino acid and β-hydroxybutyrate concentrations were determined.  This 26 
revealed increased β-hydroxybutyrate in liver from fed Pik3r1WT/Y657* mice with a 27 
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trend towards an increase in plasma, but no difference between genotypes when 1 
fasted (Figure S7A).  The fall in plasma amino acid concentrations seen in fasting 2 
wildtype mice was lost in Pik3r1WT/Y657* mice, with a trend towards a generalised 3 
increase in liver amino acids (Figure S7B,C).  These findings add to evidence for 4 
abnormal transitions between fed and fasted state in Pik3r1WT/Y657* mice, and suggest 5 
that reduced intra-hepatocyte amino acid concentrations on fasting do not explain 6 
the pronounced reduction in Rictor signaling suggested by transcriptomics. 7 
 8 
4. Discussion 9 
Most monogenic defects causing severe IR primarily affect adipose tissue 10 
development, and metabolically phenocopy common IR [1].  In contrast, humans 11 
with severe IR due to proximal insulin signalling defects do not have the 12 
dyslipidemia, fatty liver, and decreased plasma adiponectin concentration usual in 13 
common IR  [6,7,13,36].  This was first noted in people with insulin receptor 14 
mutations [13], but more recently was described in SHORT syndrome, [6,7], in which 15 
lack of fatty liver and dyslipidemia is particularly striking given concomitant 16 
lipodystrophy.  Fatty liver and atherogenic dyslipidemia are major sources of IR-17 
related morbidity, so investigating how these are dissociated from IR in the face of 18 
proximal insulin signaling defects will potentially reveal novel approaches to mitigate 19 
IR-associated disease.   20 
The novel mice generated, heterozygous for the Pik3r1 Y657* allele, show 21 
reduced growth, severe IR, and severely reduced adipose accretion on high fat 22 
feeding.   Although IR in Pik3r1R649W/WT mice described previously was reported to 23 
spare skeletal muscle[31], we found skeletal muscle to be insulin resistant both in 24 
clamps, and ex vivo, in keeping with ubiquitous expression of the mutant allele.   25 
Despite severe IR, Pik3r1WT/Y657* mice were hypolipidemic on chow or high fat 26 
diet, and in fed and fasted states, while the increase in liver triglyceride usual in 27 
lipodystrophic IR was absent, validating it as a model of the human phenomenon we 28 
 16
aimed to study.  Knockout evidence that PI3K signaling mediates insulin’s 1 
stimulation of liver de novo lipogenesis led us to expect reduced transcript levels of 2 
Srebp and its target genes (e.g. [16],[17]), however we found no evidence supporting 3 
this or other candidate transcriptional mechanisms including reduced lipogenic 4 
activity of Xbp1 [34].   5 
RNA sequencing showed most insulin-responsive genes to respond normally 6 
to fasting and refeeding.  Given elevated plasma insulin concentration this could be 7 
construed as showing compensated hepatic IR, as expected from a proximal insulin 8 
signaling defect.  Fasting-responsive programmes, such as those orchestrated by 9 
PPARα, were intact in Pik3r1Y657*/WT mice, however pathway analysis suggested 10 
reduced ER stress signaling and showed altered inflammatory signatures in the fed 11 
state, with a strikingly reduced Rictor signature in the fasted state.  These 12 
transcriptional clues may be pertinent to protection from dyslipidemia as ER stress 13 
signaling promotes fatty liver and dyslipidemia [37], while  Rictor drives hepatic 14 
lipogenesis [38], however further study is needed.  Impaired induction of Rictor 15 
activity in this case may reflect Pik3r1’s role in amino acid activation of Rictor [39]. 16 
Pik3r1R649W/WT mice have been shown to have less subcutaneous adipose 17 
tissue [31] and reduced adipose expansion in obesogenic conditions [40], as in the 18 
current report, which was interpreted as evidence of lipodystrophy.  However 19 
constrained adipose expansion produces inflammation of overloaded, hypertrophic 20 
adipose tissue during chronic positive energy balance [1], and the normal adipocyte 21 
appearance, lack of adipose inflammation, and normal differentiation of 22 
preadipocytes ex vivo in both studies argues against this [31]. 23 
Reduced adipose mass can reflect altered energy balance rather than 24 
lipodystrophy. Reduction of PI3K pathway activity by overexpression of the lipid 25 
phosphatase Pten in mice was previously reported to enhance energy expenditure 26 
via brown adipose tissue activation [41], albeit without IR, while pharmacological or 27 
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genetic inhibition of the p110α catalytic subunit of PI3K has also been associated 1 
with increased energy expenditure  [40–43].  Moreover a similar energetic phenotype 2 
has recently been described on brown adipose-specific knockout of Pik3r1 [44].  On 3 
high fat diet we found food intake and energy expenditure were both increased in 4 
Pik3r1Y657*/WT mice.  Given unaltered locomotor activity, intestinal lipid absorption, 5 
and lean tissue growth, reduced adipose accumulation shows that increased energy 6 
expenditure outweighed increased food intake, and is thus the primary abnormality.  7 
Reduced thermal insulation in smaller animals is an unlikely explanation [43], so we 8 
conclude that increased energy expenditure explains reduced adipose accretion.  9 
Increased brown adipose tissue activity is the most likely explanation, as in models 10 
with p110α inhibition[40–43], but this requires further study.   11 
Increasing brown adipose tissue function reduces plasma triglyceride and 12 
cholesterol concentrations[45,46], and this reduces atherogenesis when liver 13 
scavenging of triglyceride-depleted lipoproteins is intact [45].  This accords with the 14 
hypolipidemia of Pik3r1Y657*/WT mice, and also humans with SHORT syndrome. As 15 
brown fat is now known to occur in humans, it would be of interest to establish 16 
whether it is hyperactive in people with SHORT syndrome.  In addition, given the 17 
normal lipid profile despite severe IR in people with insulin receptor mutations [13], 18 
and the reduced adipose tissue in mice harbouring a common dominant negative 19 
insulin receptor allele on an obesogenic diet [47], it will be of interest to assess 20 
whether the bioenergetic consequences of reduced PI3K signaling are also seen in 21 
the face of insulin receptor dysfunction. 22 
5. Conclusions 23 
We report a novel mouse model of SHORT syndrome recapitulating the severe 24 
IR without dyslipidemia seen in humans. Hepatic lipogenesis and lipogenic gene 25 
expression were unimpaired, and transcriptomic pathway analysis suggested only 26 
mild nutritional state-specific abnormalities in liver gene expression.  White adipose 27 
 18
tissue was reduced on high fat diet, but did not show inflammation of hypertrophy, 1 
while energy expenditure was increased, raising the testable possibility that the 2 
reduced adipose mass in SHORT syndrome does not represent true “lipodystrophy”.  3 
The most likely mechanism explaining uncoupling of IR from dyslipidemia in SHORT 4 
syndrome is increased brown adipose activity, consistent with other murine evidence 5 
that inhibition of PI3K results in beneficial metabolic alterations as well as IR. 6 
 7 
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Tables 
 
 
 
 Chow 45% Fat Diet 
 Fasting Fed Fasting Fed 
 Pik3r1WT/WT 
(n=10) 
Pik3r1WT/Y657* 
(n=9) p 
Pik3r1WT/WT 
(n=10) 
Pik3r1WT/Y657* 
(n=14) p 
Pik3r1WT/WT 
(n=13) 
Pik3r1WT/Y657* 
(n=13) p 
Pik3r1WT/WT 
(n=15) 
Pik3r1WT/Y657* 
(n=11) p 
Glucose 
(mmol/L) 10.2 ± 1.1 9.0 ± 1.1 0.43 12.5 ± 0.7 13.2 ± 0.5 0.48 9.7 ± 0.8 7.9 ± 0.5 0.06 12.6 ± 0.5 9.4 ± 0.5 4x10
-4
 
Insulin 
(pmol/L) 138 ± 21 603 ± 202 0.05 229 ± 33 3393 ± 578 
1.9 
x10-4 469 ± 77 693 ± 102 0.09 424 ± 73 1313 ± 494 0.104 
Adiponectin 
(mg/L) 30.5 ± 1.1 26.7 ± 1.3 0.03 33.2 ± 1.5 35.6 ± 1.0 0.2 37.0 ± 1.1 40.6 ± 1.5 0.07 40.3 ± 2.2 42.8 ± 1.1 0.3 
Total 
cholesterol 
(mmol/L) 
2.7 ± 0.1 2.3 ± 0.1 0.01 2.6 ± 0.1 2.0 ± 0.1 6 x10-3 4.2 ± 0.2 3.0 ± 0.3 0.01 4.7 ± 0.3 1.7 ± 0.1 1.0x10-7 
HDL 
cholesterol 
(mmol/L) 
1.5 ± 0.1 1.1 ± 0.1 0.02 1.6 ± 0.1 1.3 ± 0.1 0.04 1.8 ± 0.2 1.2 ± 0.2 0.02 2.3 ± 0.1 0.9 ± 0.1 2.7x10-8 
Triglycerides 
(mmol/L) 1.5 ± 0.1 1.0 ± 0.1 0.01 1.6 ± 0.1 1.1 ± 0.1 0.01 1.5 ± 0.1 1.4 ± 0.1 0.15 1.0 ± 0.1 0.6 ± 0.02 3.5x10
-6
 
NEFA 
(mmol/L) 2.0 ± 0.2 1.2 ± 0.1 5 x10
-3
 1.5 ± 0.1 1.3 ± 0.2 0.3 2.5 ± 0.2 1.9 ± 0.1 0.05 1.5 ± 0.1 0.8 ± 0.1 7 x10-5 
VLDL 
(mg/mL) N.D. N.D. N.D. 7.9 ± 0.3 7.4 ± 1.2 0.25 N.D. N.D. N.D. 10.5 ± 0.5 11.9 ± 0.8 0.13 
 
Table 1. Fasting plasma biochemical profile of male Pik3r1WT/WT and Pik3r1WT/Y657* mice. See also Supplemental Table S1 for fasting 
biochemical profile for chow-fed female mice. N.D. = not determined. Statistical comparisons were undertaken using the student’s t-test. 
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Figure Legends 
 
Figure 1. Effect of Pik3r1 Y657* on prenatal development and postnatal growth. 
(A) Representative image of Pik3r1WT/WT (WT/WT) and Pik3r1WT/Y657* (WT/Y657*) 
mice at 18 weeks old. (B) Body lengths (nose to anus) at 18 weeks of Pik3r1WT/WT 
and Pik3r1WT/Y657* mice (n=11 and 18 respectively). (C) Bodyweight increase from 8 
to 16 weeks of Pik3r1WT/WT and Pik3r1WT/Y657* (n=16 and 12 respectively). (D) The 
relationship between lean and fat mass of Pik3r1WT/WT and Pik3r1WT/Y657* mice (n =16 
and 12 respectively). Masses of (E) inguinal adipose tissue (IngWAT) (F) Epididymal 
adipose tissue (eWAT), (G) Brown adipose tissue (BAT), (H) Liver, and (I) Heart of 
Pik3r1WT/WT and Pik3r1WT/Y657* mice (n= 11 and 7 respectively).  (J) Food intake (n=13 
for Pik3r1WT/WT and n=14 for Pik3r1WT/Y657*), (K) Energy expenditure and (L) 
Respiratory exchange ratio (RER) (n=7 for Pik3r1WT/WT and n=13 for Pik3r1WT/Y657*) of 
wild type and heterozygous mice assessed at 18 weeks old. All data shown are from 
male mice.  Masses and energy expenditure are shown relative to total lean mass, 
and were analysed statistically by ANCOVA. * = p < 0.05; *** = p < 0.001; **** = p < 
0.0001. Mean ± SD are shown for plots in (B), (C) and (l). 
 
Figure 2. Response of Pik3r1WT/Y657* mice to a palatable 45% fat diet. (A) 
Bodyweight increase from 8 to 16 weeks of Pik3r1WT/WT (WT/WT) and Pik3r1WT/Y657* 
(WT/Y657*) (n=16 and 12 respectively). (B) The relationship between lean and fat 
mass of Pik3r1WT/WT and Pik3r1WT/Y657* mice (n =16 and 12 respectively).  Masses of 
(C) Epididymal adipose tissue (eWAT), (D) Inguinal adipose tissue (IngWAT), (E) 
Brown adipose tissue (BAT), (F) Liver, and (G) Heart of Pik3r1WT/WT and 
Pik3r1WT/Y657* mice (n= 12 for both genotypes).  (H) Representative histological 
appearance of haematoxylin and eosin-stained eWAT from Pik3r1WT/WT and 
Pik3r1WT/Y657* mice. Scale bars = 100μm (I) Adipocyte size distribution in eWAT 
based on quantification of >1,000 cells per genotype from 4 wild type and 4 
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heterozygous mice. The inset shows a zoomed-in view of the % of cells smaller than 
10000μm2.  (J) Representative images of ex vivo differentiated stromal vascular cells 
from ingWAT stained with Oil Red O. (K) % of CD4+ and regulatory T cells in the 
eWAT (n=3 for Pik3r1WT/WT and n=3 for Pik3r1WT/Y657*). (L) Food intake (n=13 for 
Pik3r1WT/WT and n=14 for Pik3r1WT/Y657*) and (M) Energy expenditure (n=17 for 
Pik3r1WT/WT and n=10 for Pik3r1WT/Y657*) of wild type and heterozygous mice 
assessed at 18 weeks old.  All masses and energy expenditure are shown relative to 
total lean mass, and were analysed statistically by ANCOVA. (N) Locomotor activity 
of Pik3r1WT/WT and  Pik3r1WT/Y657* mice (n=17 and n-10 respectively). (O) Respiratory 
exchange ratio (RER) (n=17 for Pik3r1WT/WT and n=10 for Pik3r1WT/Y657*) of wild type 
and heterozygous mice assessed at 18 weeks old. All data shown are from male 
mice.  Mean ± SD are shown. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. 
 
Figure 3. Pik3r1WT/Y657* mice show systemic and tissue-level insulin resistance. 
(A) Glucose infusion rates during hyperinsulinemic euglycemic clamping of 
Pik3r1WT/WT (WT/WT) and Pik3r1WT/Y657* (WT/Y657*) mice on chow (n=4 and 4) or 
45% fat diet (n=10 and 11) at 16 weeks old. (B) Oral glucose tolerance test (OGTT) 
and corresponding comparison of areas under the curves (AUC) of Pik3r1WT/WT and 
Pik3r1WT/Y657* mice on chow at 12 weeks old (n=10 and 9). (C) Insulin concentrations 
and AUC for the same OGTT as in (B). (D) Insulin tolerance test and AUC 
comparison for the same mice 1 week later. (E) Glucose disposal and (F) 
suppression of hepatic glucose output by insulin during hyperinsulinemic euglycemic 
clamping of Pik3r1WT/WT and Pik3r1WT/Y657* mice on chow at 18 weeks old (both n=4). 
(G) Glycogen content of livers during a fasting-refeeding cycle in chow fed animals 
at 16 weeks old (both n=6). (H) Plasma non-esterified free fatty acid concentrations 
during hyperinsulinemic euglycemic clamping (both genotypes n=4). (I)-(L) 
Representative images of immunoblots and corresponding quantifications of tissue 
lysates from mice injected intraperitoneally with 2U/kg insulin 10 mins prior to 
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sacrifice, showing pAktSer473, total Akt and their ratio: (I) Liver, (J) Skeletal muscle (K) 
eWAT, (L) ingWAT.  (n=6 per genotype and condition). (M) Insulin-induced fold 
increase of glucose uptake into ex vivo incubated soleus (n=18 for Pik3r1WT/WT, n=11 
for Pik3r1WT/Y657*) and Extensor Digitorum Longus (EDL) (n=20 and 11). (N) 
Representative immunoblots of Soleus and EDL lysates from the same paradigm as 
in (M). (O) Quantification of pAkt Ser473 to total Akt ratios from soleus and EDL 
immunoblots (n=5 and 4 for both). Data are from male mice.  Quantitative data are 
presented as mean ± SD. * = p < 0.05, ** = p < 0.01, *** = p < 0.001 and **** = p < 
0.0001. 
 
Figure 4. Lipid handling and liver phenotype of Pik3r1WT/Y657* mice. (A) 
Representative images of Oil-Red-O-stained livers of chow-fed and 45% fat diet-fed 
Pik3r1WT/WT (WT/WT) and Pik3r1WT/Y657* (WT/Y657*) mice. Scale bars = 200μm. (B) 
Hepatic triglyceride and  (C) Hepatic total cholesterol concentration during a fasting 
refeeding cycle of chow fed mice at 16 weeks old (n=6 per genotype). (D) Lipid 
tolerance testing and comparison of areas under the curve (AUC), also of chow-fed 
mice, at 16 weeks old.  Triglyceride concentrations were equalised at baseline by 
matching the difference between genotypes with the lower values of heterozygous 
mice, and the same fixed correction was applied to all points on the graph (n = 11 
and n=17 for wild-type and heterozygous mice respectively). (E) Faecal energy 
content determined by bomb calorimetry of chow fed mice at 16 weeks old (n=8 and 
8). (F) De novo palmitate  measured by stable deuterium enrichment (n=7 and n=10 
for wild-type and heterozygous mice respectively). (G)-(M) Liver mRNA expression, 
determined by quantitative real time PCR of (G) Srebp1 and its transcriptional 
targets (H) Acc1, (I) Fasn, and (J) Scd1, and of (K) Srebp2 and its transcriptional 
targets (L) Mvk and (M) Nsdhl in chow fed mice during a fasting refeeding cycle at 
16 weeks old (n=6 per genotype per condition).  All data shown are from male mice.  
Numerical data are presented as mean ± SD.  
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Figure 5.  Pathway analysis of liver transcriptomes of fed and fasted mice. 
Volcano plots are shown for predicted upstream regulators derived from Ingenuity® 
Pathway Analysis (IPA®) of transcriptomes of fed and fasted male  Pik3r1WT/Y657* 
(n=6,6) mice and wildtype littermates (n=6,6). Outside plots show regulators showing 
differential activity in the fasting state compared to the fed state for wildtype (WT; 
left) and Pik3r1WT/Y657* (right) mice.  Central plots show regulators with differential 
activity in Pik3r1WT/Y657* vs WT mice in the fed state (top) and fasting state (bottom).  
Green dots represent data point with an activation z score < -2 or > +2 and a p-value 
< 1 x 10-5. Regulators showing differential activity in either genotype-based 
comparison are coloured red (activation z score > +2  in Pik3r1WT/Y657* vs WT mice) 
or blue (activation z score < -2  in Pik3r1WT/Y657* vs WT mice) in the outside plots 
showing differences based on nutritional state.  Statistical analysis was performed 
using a general linear model with Bonferroni correction. 
Fig. 1
10am 6pm 6am 10am
0.7
0.8
0.9
1.0
1.1
RER on chow fed mice 
WT/WT
WT/Y657*
Light cycle Dark cycle Light cycle
Time
RE
R
WT/WT WT/Y657*
14 16 18 20 22 24 26
0.0
0.1
0.2
0.3
Lean mass (g)
B
AT
 (g
)
Pik3r1WT/WT
Pik3r1WT/Y657X
p=0.987
14 16 18 20 22 24 26
0.0
0.5
1.0
1.5
2.0
2.5
Lean mass (g)
eW
AT
 (g
)
p=0.194
Pik3r1WT/WT
Pik3r1WT/Y657X
14 16 18 20 22 24 26
0.0
0.5
1.0
1.5
Lean mass (g)
In
gW
AT
 (g
)
p=0.181
Pik3r1WT/WT
Pik3r1WT/Y657X
14 16 18 20 22 24 26
0
5
10
15
Lean mass (g)
Fa
t m
as
s 
(g
)
Pik3r1WT/WT
Pik3r1WT/Y657X
*
i r /
i r / 657*
Pik3r1WT/WT
Pik3r1WT/Y657*
Pik3r1WT/WT
Pik3r1WT/Y657*
WT
/W
T
WT
/Y6
57
*
0
50
100
150
Le
ng
th
 (m
m
)
***
5 10 15 20
15
20
25
30
35
40
Time (weeks)
B
W
 (g
)
WT/WT
WT/Y657*
****
WT/WT
WT/Y657*
WT/WT
WT/Y657*
WT/WT
WT/Y657*
WT/WT
WT/Y657*
WT/WT
WT/Y657*
WT/WT
WT/Y657*
WT/WT
WT/Y657*
WT/WT
WT/Y657*
A B C
E F G
H I
K L
D
J
Fig. 2
WT
/W
T
WT
/Y6
57
*
0
10
20
30
40
50
Be
am
 b
re
ak
s/
m
in
WT
/W
T
WT
/Y6
57
*
0
20
40
60
80
Be
am
 b
re
ak
s/
m
in
WT
/W
T
WT
/Y6
57
*
0
2
4
6
8
10
 C
D
4+
 F
ox
p3
+  c
el
ls
 (%
)
Treg cells
WT
/W
T
WT
/Y6
57
*
0
20
40
60
80
100
C
D
4+
 c
el
ls
 (%
)
WT
/W
T
WT
/Y6
57
*
0
2
4
6
8
10
Li
ve
 ly
m
ph
oc
yt
es
 in
 e
W
AT
 (%
)
10am 6pm 6am 10am
0.80
0.85
0.90
0.95
RER-(45%HFD)(last 24h from 10am)
Time
R
ER
WT/WT
WT/Y657*
Light cycle Dark cycle Light cycle
0
10
00
0
20
00
0
30
00
0
40
00
0
50
00
0
60
00
0
70
00
0
80
00
0
90
00
0
10
00
00
0
10
20
30
Cell size (µm2)
%
 o
f c
el
ls
WT/WT
WT/Y657*
5 10 15 20
10
20
30
40
50
Time (weeks)
B
W
 (g
)
WT/WT
WT/Y657*
****
WT/WT
WT/Y657*
WT/WT
WT/Y657*
Overall Dark cycle Light cycle
14 16 18 20 22 24 26
0
5
10
15
20
25
Lean mass (g)
Fa
t m
as
s 
(g
)
****
Pik3r1WT/WT
Pik3r1WT/Y657X
5 10 15 20
10
20
30
40
50
Time (weeks)
B
W
 (g
)
WT/WT
WT/Y657*
****
5 10 15 20
10
20
30
40
50
Time (weeks)
B
W
 (g
)
WT/WT
WT/Y657*
****
5 10 15 20
10
20
30
40
50
Time (weeks)
B
W
 (g
)
WT/WT
WT/Y657*
****
5 10 15 20
10
20
30
40
50
Time (weeks)
B
W
 (g
)
WT/WT
WT/Y657*
****
5 10 15 20
10
20
30
40
50
Time (weeks)
B
W
 (g
)
WT/WT
WT/Y657*
****
5 10 5 20
10
20
30
40
50
Time (weeks)
B
W
 (g
)
WT/WT
WT/Y657*
****
5 10 15 20
10
20
30
40
50
Time (weeks)
B
W
 (g
)
WT/WT
WT/Y657*
****
5 10 15 20
10
20
30
40
50
Time (weeks)
B
W
 (g
)
WT/WT
WT/Y657*
****
0
20
00
40
00
60
00
80
00
10
00
0
0
10
20
30
%
 o
f c
el
ls
WT/WT
WT/Y657*
Cell size (µm2)
WT
/W
T
WT
/Y6
57
*
0
50
100
150
Be
am
 b
re
ak
s/
m
in *
A B C
D E F
G H I J
K L M
N O
Basal Insulin Basal Insulin 
0
1
2
3
A
.U
****
WT/Y657*WT/WT
Basal Insulin Basal Insulin 
0.0
0.5
1.0
1.5
A
.U
.
********
WT/Y657*WT/WTWT
/W
T
WT
/Y6
57
* 
0
1
2
3
4
5
G
lu
co
se
 u
pt
ak
e 
(A
.U
.) *
WT
/W
T
WT
/Y6
57
* 
0
1
2
3
G
lu
co
se
 u
pt
ak
e 
(A
.U
.)
*
Basal Insulin Basal Insulin 
0.0
0.5
1.0
1.5
A
.U
.
****
WT/Y657*WT/WT
Basal Insulin Basal Insulin 
0.0
0.5
1.0
1.5
A
.U
.
p=0.079
WT/Y657*WT/WT
Basal Insulin Basal Insulin 
0.0
0.5
1.0
1.5
A
.U
.
**
WT/Y657*WT/WT
Basal Insulin Basal Insulin 
0.0
0.5
1.0
1.5
2.0
A
.U
.
***
WT/Y657*WT/WT
W
T/
W
T
W
T/
Y
65
7*
 
W
T/
W
T
W
T/
Y
65
7*
 
W
T/
W
T
W
T/
Y
65
7*
 0
100
200
300
400
Ad. lib Overnight
Fasting
Refed
G
ly
co
ge
n 
co
nt
en
t 
(m
m
ol
/k
g 
w
et
 w
ei
gh
t)
WT
/W
T
WT
/Y6
57
* 
0.0
0.5
1.0
1.5
2.0
St
ea
dy
 s
ta
te
 R
d/
B
as
al
 R
d *
WT
/W
T
WT
/Y6
57
* 
0
50
100
150
Su
pp
re
ss
io
n 
of
 
gl
uc
os
e 
pr
od
uc
tio
n 
(%
)
*
WT
/W
T
WT
/Y6
57
* 
0
10000
20000
30000
A
U
C
 (m
in
s.
pm
ol
/L
)
Basal Insulin Basal Insulin 
0.0
0.5
1.0
1.5
2.0
2.5
Fr
ee
 fa
tty
 a
ci
ds
 (m
M
)
WT/Y657*WT/WT
***
WT
/W
T
WT
/Y6
57
*
0
500
1000
1500
2000
A
U
C
 (m
in
s.
m
m
ol
/L
)
**
0 50 100 150
0
5
10
15
20
Time (mins)
G
lu
co
se
 (m
m
ol
/L
)
WT/WT
WT/Y657*
**
0 20 40 60 80 100
0
200
400
600
Time (Mins)
In
su
lin
 (p
m
ol
/L
)
WT/WT
WT/Y657*
0 20 40 60 80 100
0
100
200
300
Mins
G
IR
 (u
L/
h)
WT/WT on Chow
WT/Y657* on Chow
WT/WT on 45% HFD
WT/Y657* on 45% HFD
****
WT
/W
T
WT
/Y6
57
*
0
1000
2000
3000
A
U
C
 (m
in
s.
m
m
ol
/L
)
p=0.052
0 50 100 150
0
10
20
30
40
Time (Mins)
G
lu
co
se
 (m
m
ol
/L
)
WT/WT
WT/Y657*
pAkt (S473)
- + - +Insulin
WT/WT WT/Y657*
Total Akt
β-actin
pAkt (S473)
Total Akt
β-actin
- + - +Insulin
WT/WT WT/Y657*
- + - +
WT/WT
Insulin
WT/Y657*
pAkt (S473)
Total Akt
β-actin
So
le
us
 
ED
L
- +
WT/WT 
- +
So
le
us
 
ED
L
- +
WT/Y657*
- +
pAkt (S473)
Insulin
Total Akt
GAPDH
- + - +
pAkt (S473)
Total Akt
β-actin
WT/WT WT/Y657*
Liver Skeletal muscle
eWAT ingWAT
Soleus EDL Soleus EDL
A B C
D E HF G
I J
K L
M ON
Fig. 3
W
T/
W
T
W
T/
Y
65
7*
W
T/
W
T
W
T/
Y
65
7*
W
T/
W
T
W
T/
Y
65
7*
0
50
100
150
200
A
.U
.
Nsdhl
Ad lib. Overnight 
fasting
Refed
W
T/
W
T
W
T/
Y
65
7*
W
T/
W
T
W
T/
Y
65
7*
W
T/
W
T
W
T/
Y
65
7*
0
100
200
300
400
A
.U
.
Mvk
Ad lib. Overnight 
fasting
Refed
W
T/
W
T
W
T/
Y6
57
*
W
T/
W
T
W
T/
Y6
57
*
W
T/
W
T
W
T/
Y6
57
*0
50
100
150
200
250
A
.U
.
Srebp2
Ad lib. Overnight 
fasting
Refed
W
T/
W
T
W
T/
Y6
57
*
W
T/
W
T
W
T/
Y6
57
*
W
T/
W
T
W
T/
Y6
57
*0
50
100
150
200
250
A
.U
.
Scd1
Ad lib. Overnight 
fasting
Refed
W
T/
W
T
W
T/
Y
65
7*
W
T/
W
T
W
T/
Y
65
7*
W
T/
W
T
W
T/
Y
65
7*
0
50
100
150
200
A
.U
.
Fasn
Ad lib. Overnight 
fasting
Refed
W
T/
W
T
W
T/
Y
65
7*
W
T/
W
T
W
T/
Y
65
7*
W
T/
W
T
W
T/
Y
65
7*
0
50
100
150
200
A
.U
.
Acc1
Ad lib. Overnight 
fasting
Refed
W
T/
W
T
W
T/
Y
65
7*
W
T/
W
T
W
T/
Y
65
7*
W
T/
W
T
W
T/
Y
65
7*
0
50
100
150
Ad lib. Overnight 
fasting
Refed
A
.U
.
Srebp1
W
T/
W
T
W
T/
Y
65
7*
W
T/
W
T
W
T/
Y
65
7*
20
25
30
35
40
45
%
 o
f C
16
:0
 e
nr
ic
hm
en
t
Plamsa Liver
WT
/W
T
WT
/Y6
57
* 
15000
20000
25000
30000
Fa
ec
al
 e
ne
rg
y 
(J
)
WT
/W
T
WT
/Y6
57
* 
0
10
20
30
40
50
A
U
C
 (h
rs
.m
m
ol
/L
)
p=0.22
0 2 4 6 8 10
0
200
400
600
800
1000
Time (hours)
Tr
ig
ly
ce
rid
e 
le
ve
l 
(%
 to
 b
as
al
 le
ve
l)
WT/WT
WT/Y657* 
W
T/
W
T
W
T/
Y6
57
* 
W
T/
W
T
W
T/
Y6
57
* 
W
T/
W
T
W
T/
Y6
57
* 
0.0
0.5
1.0
1.5
He
pa
tic
 c
ho
le
st
er
ol
 le
ve
l (
m
g/
g)
P=0.058
Ad lib. Overnight 
fasting
Refed
W
T/
W
T
W
T/
Y
65
7*
 
W
T/
W
T
W
T/
Y
65
7*
 
W
T/
W
T
W
T/
Y
65
7*
 0
10
20
30
Tr
ig
ly
ce
rid
e 
le
ve
l i
n 
liv
er
 (m
g/
g)
Ad. lib Overnight
Fasting
Refed
WT/WT, Chow WT/Y657*, Chow WT/WT, 45% HFD WT/Y657*, 45% HFDA
B C D
F G H I
J K L
Fig. 4
E
M
Ac#va#on	z	score	
-lo
g1
0(
p-
ov
er
la
p)
	
Pik3r1Y657X	vs	WT	(fas(ng)	
Pik3r1Y657X	vs	WT	(fed)	
Fas1ng	vs	Fed	(Pik3r1Y657X)	Fas1ng	vs	Fed	(WT)	
-10															-5																	0																		5																	10	
-10															-5																	0																		5																	10	
-10															-5																	0																		5																	10	
35	
30	
25	
20	
15	
10	
5	
0	
	
35	
30	
25	
20	
15	
10	
5	
0	
	
-10															-5																	0																		5																	10	
40	
30	
20	
10	
0	
	
25	
20	
15	
10	
5	
0	
	
Liver	RNAseq	
Pirinixic	acid*	
Ppara*	
Por	
Dexamethasone	
Fenofibrate*	
Bezafibrate*	
Mycn	
Xbp1	
Rictor	
Sirolimus	
Mycn	
Myc	
Pirinixic	acid*	
Ppara*	
ciprofibrate*	Por	
fenofibrate*	bezafibrate*	
clofibrate*	
Xbp1	
IL-6	
Ern1	
Xbp1	
mir223	
App	
Ifng	
Atf6	
Ptger4	
Por	
Kras	
Methylprednisolone	
Acox1	ST1926	Tretinion	
TP53	
Ppara	
Pparg	
Hnf1a	
Ifna2	
ciprofibrate*		
Trim24	
Sirolimus	
Methylprednisolone	
Acox1	
Tunicamycin	
Srebp2	
Ern1	
Scap	
Myc	
Hnf1a	
Srebp1	
Mycn	
Slc13a1	
Pgc1	
Klf15	
Rosiglitazone	
Sterol	
Trim24	
Tunicamycin	
Srebp2	
Acox1	
Srebp1	
Scap	
Rictor	
Ern1	
App	
Pparg	
Insig1	
Insig1	
Clofibrate*	
Ciprofibrate*	
IL21	
Ifna2	
UDP-glucose	
Tretinion	
Stat1	
Rictor	
WT/Y657* vs WT/WT (fed)
WT/Y6 * vs WT/WT (fasting)
Fasting vs Fed (WT/Y 7*)Fasting vs Fed (WT/WT)
Fig. 5
Highlights 
 
 
 
Truncation of Pik3r1 causes severe insulin resistance uncoupled 
from obesity and dyslipidemia by increased energy expenditure 
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• Human SHORT syndrome includes severe insulin resistance and 
lipodystrophy 
 
• Unlike other lipodystrophies, fatty liver and dyslipidaemia are not seen 
 
• A mouse model with a pathogenic human PI 3-Kinase mutation 
recapitulates this uncoupling 
 
• Surprisingly, no adipose injury nor increased liver de novo lipogenesis are 
seen 
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• This increases evidence for some beneficial metabolic effects of PI 3-Kinase 
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